bpc-157 fda warning 2024 panel backs compounded BPC-157, KPV peptides in win for RFK Jr fda warning letter bpc-157 2024

Endogenous MOTS-c levels decline as we age

the FDA has stated it lacks sufficient information to know whether the substance would cause harm when administered to humans Evidence snapshot: The evidence base is almost entirely preclinical, decades of animal (largely rat) studies, mostly from one Croatian research group (Sikiric et al., University of Zagreb), with a single small human trial under the brand name "Bepecin" (around 2015) that did not lead to any FDA-approved use

Information on BPC-157 dosages comes primarily from preclinical studies and research protocols

OPM database and PPM web server: resources for positioning of proteins in membranes

Been using for 3 wks